The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1611
November 16, 2020
View Complete Issue         Table of Contents 2019 
Minocycline Foam (Zilxi) for Rosacea
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Minocycline Foam (Zilxi) for Rosacea
November 16, 2020 (Issue: 1611)
The FDA has approved a 1.5% topical foam formulation of minocycline (Zilxi – Foamix) for treatment of inflammatory lesions of rosacea in adults. It is the only topical minocycline product approved for this indication. The same manufacturer...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Minocycline Foam (Zilxi) for Rosacea
Article code: 1611c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.